Negative Ames and in vivo rat micronucleus/comet; clastogenic in vitro in human lymphocytes; overall no genotoxic risk
“Darolutamide was clastogenic in an in vitro chromosome aberration assay in human peripheral blood lymphocytes. However, darolutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in an in vivo combined bone marrow micronucleus assay and comet assay in the liver and duodenum of the rat.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗
Carcinogenicity
Not conducted (advanced cancer indication)
“No carcinogenicity studies were conducted or warranted to support this NDA, as the proposed indication was for advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗
Reproductive & developmental
No dedicated studies; male reproductive organ atrophy in repeat-dose studies, fertility may be impaired
“No embryo-fetal development toxicology studies were conducted or warranted to support this NDA submission, as the proposed indication does not include females.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗
Safety pharmacology
Low-potency hERG blocker (IC50 >1 µM); IV vasodilation in anaesthetized dogs; no ECG changes in repeat-dose dogs; low CNS risk
“In vitro, darolutamide, (S,R)-darolutamide, (S,S)-darolutamide and keto-darolutamide were low-potency hERG channel blockers (IC50 > 1 µM).”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative